AstraZeneca subpoenaed
This article was originally published in The Tan Sheet
Executive Summary
Pennsylvania U.S. Attorney is seeking documents related to the formulary status of proton pump inhibitors Prilosec and Nexium at a regional health maintenance organization and a national pharmacy benefits manager, AstraZeneca announces in recent third-quarter earnings report. The firm says it "intends to cooperate fully" with the document requests. AstraZeneca's Nexium marketing is the target of a consumer suit filed in U.S. Superior Court last month (1"The Tan Sheet" Oct. 24, 2004, p. 11)...
You may also be interested in...
AstraZeneca’s Nexium Marketing Targeted In Consumer Suit
A lawsuit filed in U.S. Superior Court in Los Angeles alleges AstraZeneca employed "unfair and deceptive" practices in promoting its proton pump inhibitor Nexium (esomeprazole)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.